PAR2‐mediated cellular senescence promotes inflammation and fibrosis in aging and chronic kidney disease
Aging Cell · 2024-08 · 23 (8)
DOI: 10.1111/acel.14184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, online erschienen am 30.04.2024. Verfasst von Sugyeong Ha und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan, Korea. Hauptthemen laut MEDLINE: Cellular Senescence, Fibrosis, Receptor, PAR-2, Inflammation. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Cellular senescence contributes to inflammatory kidney disease via the secretion of inflammatory and profibrotic factors. Protease‐activating receptor 2 (PAR2) is a key regulator of inflammation in kidney diseases. However, the relationship between PAR2 and cellular senescence in kidney disease has not yet been described. In this study, we found that PAR2‐mediated metabolic changes in renal tubular epithelial cells induced cellular senescence and increased inflammatory responses. Using an aging and renal injury model, PAR2 expression was shown to be associated with cellular senescence. Under in vitro conditions in NRK52E cells, PAR2 activation induces tubular epithelial cell senescence and senescent cells showed defective fatty acid oxidation (FAO). Cpt1α inhibition showed similar senescent phenotype in the cells, implicating the important role of defective FAO in senescence. Finally, we subjected mice lacking PAR2 to aging and renal injury. PAR2‐deficient kidneys are protected from adenine‐ and cisplatin‐induced renal fibrosis and injury, respectively, by reducing senescence and inflammation. Moreover, kidneys lacking PAR2 exhibited reduced numbers of senescent cells and inflammation during aging. These findings offer fresh insights into the mechanisms underlying renal senescence and indicate that targeting PAR2 or FAO may be a promising therapeutic approach for managing kidney injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy and Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan, Korea.
- Department of Parasitology and Tropical Medicine, School of Medicine, Pusan National University, Yangsan, Korea.
ORCID-Profile: Hae Young Chung, Ki Wung Chung
Förderung
- National Research Foundation of Korea
Zitieren
APA
Ha, S., Kim, H. W., Kim, K. M., Kim, B. M., Kim, J., Son, M., Kim, D., Kim, M. J., Yoo, J., Yu, H. S., Jung, Y. S., Lee, J., Chung, H. Y., & Chung, K. W. (2024). PAR2‐mediated cellular senescence promotes inflammation and fibrosis in aging and chronic kidney disease. Aging Cell, 23(8). https://doi.org/10.1111/acel.14184
Vancouver
Ha S, Kim HW, Kim KM, Kim BM, Kim J, Son M, et al. PAR2‐mediated cellular senescence promotes inflammation and fibrosis in aging and chronic kidney disease. Aging Cell. 2024;23(8). doi:10.1111/acel.14184
BibTeX
@article{Ha2024,
author = {Ha, Sugyeong and Kim, Hyun Woo and Kim, Kyung Mok and Kim, Byeong Moo and Kim, Jeongwon and Son, Minjung and Kim, Doyeon and Kim, Mi-Jeong and Yoo, Jian and Yu, Hak Sun and Jung, Young-Suk and Lee, Jaewon and Chung, Hae Young and Chung, Ki Wung},
title = {PAR2‐mediated cellular senescence promotes inflammation and fibrosis in aging and chronic kidney disease},
journal = {Aging Cell},
year = {2024},
volume = {23},
number = {8},
doi = {10.1111/acel.14184}
}
EUVIMED